Multipotent and Unipotent Cells: Specialization and iPS Cells Revision Notes | A Level AQA Biology

1. From One Cell to Trillions: The Potency Problem

Every cell in your body carries the same DNA — yet a neuron looks and behaves nothing like a cardiomyocyte. The question that drives this entire topic is: how does a cell decide what to become? The answer lies in which genes are switched on or off, and that decision is shaped by the cell's potency — the range of cell types it is still capable of producing.

Potency is not fixed for life. Early in development, cells are highly flexible. As development proceeds, that flexibility narrows — and understanding exactly how and where it narrows is central to the AQA specification on gene expression control.

2. A Hierarchy of Potency: Pluripotent, Multipotent, and Unipotent

Picture a branching tree. At the very top sits a single fertilised egg — totipotent, capable of forming every cell type including placental tissue. Just below that, in the inner cell mass of the early embryo, are pluripotent cells. These can differentiate into almost any cell type in the body, but not placental tissue. Pluripotent cells are found in embryos, and this is the key location detail the specification requires you to state.

As the embryo develops into a mature mammal, pluripotency gives way to more restricted states. The branches of the tree narrow. Cells become either multipotent — able to produce a limited range of related cell types — or unipotent — able to produce only one specific cell type. Both multipotent and unipotent cells are found in mature mammals, where they maintain and repair tissues throughout life.

Notice the pattern: as potency decreases, location shifts from embryo to adult tissue. This is not coincidence — it reflects the progressive switching-off of genes that control alternative developmental pathways, a direct consequence of gene expression control mechanisms such as DNA methylation and histone modification.

3. Unipotent Cells in Action: The Formation of Cardiomyocytes

The specification asks you to use cardiomyocyte formation as your named example of unipotent cell specialisation. Cardiomyocytes are the contractile muscle cells of the heart — the cells responsible for every heartbeat. They are produced from cardiac progenitor cells, which are unipotent: they can divide and differentiate, but only into cardiomyocytes.

During development, cardiac progenitor cells receive specific signalling molecules that activate a precise set of transcription factors — proteins including GATA4, Nkx2-5, and MEF2C. These transcription factors bind to the promoter regions of cardiac-specific genes, switching on the expression of proteins needed for muscle contraction (such as cardiac troponin and myosin heavy chain) while keeping all other lineage genes silenced.

The result is a cell with a highly specialised structure: cardiomyocytes contain densely packed myofibrils, abundant mitochondria to sustain continuous aerobic respiration, and intercalated discs that allow electrical signals to pass rapidly between cells. Every structural feature is a direct product of the gene expression pattern established by those transcription factors.

Here is where the biology becomes clinically significant. Adult cardiomyocytes have very limited capacity to divide. When heart muscle is damaged — for example, after a myocardial infarction — the unipotent cardiac progenitor cell population is insufficient to replace the lost tissue at scale. This limitation is precisely why researchers have turned to a different strategy: reprogramming cells to restore pluripotency.

4. Reversing the Clock: Induced Pluripotent Stem (iPS) Cells

For decades, scientists assumed that differentiation was a one-way street — once a cell committed to a fate, that commitment was permanent. In 2006, Shinya Yamanaka's laboratory overturned this assumption. They showed that adult somatic cells (fully differentiated body cells) could be reprogrammed back to a pluripotent state by introducing just four specific protein transcription factors. These reprogrammed cells are called induced pluripotent stem cells, or iPS cells.

The four transcription factors used in the original work — Oct4, Sox2, Klf4, and c-Myc — are proteins that are normally active in embryonic stem cells. When introduced into an adult somatic cell (such as a skin fibroblast), they bind to the regulatory regions of pluripotency genes and reactivate them, while simultaneously silencing the differentiation-specific gene expression pattern that defined the original cell type.

The mechanism connects directly back to gene expression control: these transcription factors alter which regions of chromatin are accessible, reversing the epigenetic marks (such as DNA methylation and histone modifications) that had locked the cell into its differentiated state. The cell's gene expression profile is effectively reset to resemble that of an embryonic pluripotent cell.

Worked example: How iPS Cells Are Produced from Adult Somatic Cells

Describe, in sequence, the process by which an adult skin cell is converted into an iPS cell.

1. An adult somatic cell — commonly a skin fibroblast — is isolated from the patient. — Fibroblasts are used because they are accessible and relatively straightforward to culture. The cell is fully differentiated and has a fixed gene expression pattern.
2. Genes encoding the reprogramming transcription factors (e.g. Oct4, Sox2, Klf4, c-Myc) are delivered into the cell, typically via a viral vector. — The viral vector carries the transcription factor genes into the cell's nucleus. The AQA specification states that 'appropriate protein transcription factors' are used — you do not need to memorise the specific factor names, but understanding their role as gene regulators is essential.
3. The introduced genes are transcribed and translated, producing the reprogramming transcription factor proteins inside the cell. — These proteins are the agents of change. They bind to DNA at the regulatory regions of pluripotency genes.
4. The transcription factors reactivate pluripotency genes and silence differentiation-specific genes by altering chromatin structure and reversing epigenetic marks. — This is the core mechanism linking iPS cell production to gene expression control. Methylation patterns and histone acetylation states are altered, changing which genes are accessible for transcription.
5. After several weeks, colonies of cells expressing pluripotency markers (such as Oct4 and Sox2 proteins) are identified and isolated. — Not every cell reprograms successfully. Selected colonies are verified to confirm they have regained pluripotency — the ability to differentiate into a wide range of cell types.

Answer: An adult somatic cell is reprogrammed to pluripotency by introducing appropriate protein transcription factors, which reactivate pluripotency genes and silence differentiation-specific gene expression, producing an iPS cell capable of differentiating into a wide range of cell types.

5. Comparing Potency Types: A Synthesis

Now that all three potency types are established, it is worth drawing the comparisons that exam questions frequently demand. The critical distinctions are location, differentiation range, and — for iPS cells — the mechanism by which pluripotency is achieved or restored.

Pluripotent cells in embryos achieve their state through the normal developmental programme: pluripotency genes are active from the outset. Multipotent and unipotent cells in mature mammals have had those genes progressively silenced through epigenetic mechanisms as differentiation proceeded. iPS cells are unique because pluripotency is artificially restored in a cell that had already completed differentiation — a reversal of the normal developmental direction.

6. Exam Technique: Answering Questions on Stem Cell Potency and iPS Cells

Questions on this topic tend to target three areas: precise definitions with correct location, the mechanism of iPS cell production, and the ability to compare potency types. Each requires a slightly different approach.

When asked to describe or state the difference between multipotent and unipotent cells, always include both the location (mature mammals) and the differentiation range. Stating only one of these typically earns only partial credit. When asked to explain how iPS cells are produced, the mark scheme will look for reference to adult somatic cells, the introduction of protein transcription factors, and the outcome of restored pluripotency — all three elements are needed for full marks.

For evaluate or suggest questions about iPS cells, consider both the advantages (patient-specific cells avoid immune rejection; no embryo destruction) and the limitations (reprogramming efficiency is low; risk of uncontrolled cell division if oncogenes such as c-Myc are used). A conclusion that weighs these points is required for the highest mark bands.